U.S retail drug store chain Rite Aid Corporation (NYSE:RAD) recently saw its same-store sales jump 3.3%. A comparison of the figures for the corresponding period the year before for the five weeks that ended February 28, 2015. Additionally, front-end same store sales also increased by 1.6% for the month of February. The company also saw Pharmacy same store sales, inclusive of a figure of about 144 base points. This was the result of new generic introductions impacting negatively by increasing to 4.1%. The company’s prescription total also rose when compared to the previous year period by 2.2%.
Financial figures for the five weeks period ended February 28, 2015, showed that the sum sale of its drugstores rose by $44 million up from $$2.513 billion to $2.557 billion. A figure when compared to that of the previous year. Additionally, prescription sales from third party accounted for 97.6% of pharmacy sales. On the other hand for drugstore sales 69.2% represented prescription sales.
For the 13-week period ended February 28, 2015, a 4.5% jump was recorded when compared to the figures for the year before for same store sales. Additionally a jump of 2.0% accounted for Front-end same store sales, and a rise of 5.7% was recorded for pharmacy same store sales. A 3.5% increase over the corresponding period was recorded for prescription; this measured over comparable stores. For the corresponding period, Drugstore sales saw an increase of 3.5% rising by $231 million up from 6.564 billion to $6.795 billion. This figure was again in comparison with the previous year. Prescription sales by the third party accounted for 97.5% of pharmacy sales for the same period ended February 28, 2015. Additionally, prescription sales accounted for 68.1% of the sum of drugstore sales.
For the yearly period ended 52 weeks as at February 28, 2015, an increase of 4.3% was recorded over the same period for same store sales. Total drugstore sale rose by 3.7% to end with sales of $26.345 billion.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: